

Antonio Biagio Torsello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9363434/publications.pdf>

Version: 2024-02-01

98
papers

4,059
citations

117453

34
h-index

128067

60
g-index

101
all docs

101
docs citations

101
times ranked

3594
citing authors

#	ARTICLE	IF	CITATIONS
1	miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3486.	1.8	1
2	Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3054.	1.8	26
3	Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia: A meta-analysis. <i>Pharmacological Research</i> , 2021, 166, 105515.	3.1	24
4	Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. <i>Pharmaceuticals</i> , 2021, 14, 444.	1.7	6
5	Resolvin E1 and Cytokines Environment in Skeletally Immature and Adult ACL Tears. <i>Frontiers in Medicine</i> , 2021, 8, 610866.	1.2	11
6	The role of androgens in women's health and wellbeing. <i>Pharmacological Research</i> , 2021, 171, 105758.	3.1	30
7	Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. <i>Drug Target Insights</i> , 2021, 15, 26-33.	0.9	7
8	TLQP-21, A VGF-Derived Peptide Endowed of Endocrine and Extraendocrine Properties: Focus on In Vitro Calcium Signaling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 130.	1.8	9
9	Androgen Therapy in Neurodegenerative Diseases. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa120.	0.1	32
10	Characterization of Synovial Cytokine Patterns in Bucket-Handle and Posterior Horn Meniscal Tears. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	1.4	7
11	Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer's disease. <i>Stem Cells Translational Medicine</i> , 2020, 9, 1068-1084.	1.6	130
12	Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1242.	1.8	75
13	JMV5656, a short synthetic derivative of TLQP-21, alleviates acid-induced lung injury and fibrosis in mice. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 62, 101916.	1.1	1
14	Angiotensin-(1-7) exerts a protective action in a rat model of ventilator-induced diaphragmatic dysfunction. <i>Intensive Care Medicine Experimental</i> , 2019, 7, 8.	0.9	11
15	Growth Hormone Secretagogues and the Regulation of Calcium Signaling in Muscle. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4361.	1.8	7
16	miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir. <i>Frontiers in Pharmacology</i> , 2019, 10, 461.	1.6	15
17	Role of interleukin-10 in the synovial fluid of the anterior cruciate ligament injured knee. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 932-940.	0.5	10
18	Study of the Tissue Distribution of TLQP-21 in Mice Using [18F]JMV5763, a Radiolabeled Analog Prepared via [18F]Aluminum Fluoride Chelation Chemistry. <i>Frontiers in Pharmacology</i> , 2018, 9, 1274.	1.6	8

#	ARTICLE	IF	CITATIONS
19	STIM Proteins and Orai Ca ²⁺ Channels Are Involved in the Intracellular Pathways Activated by TLQP-21 in RAW264.7 Macrophages. <i>Frontiers in Pharmacology</i> , 2018, 9, 1386.	1.6	6
20	Intra-Articular Cytokine Levels in Adolescent Patients after Anterior Cruciate Ligament Tear. <i>Mediators of Inflammation</i> , 2018, 2018, 1-8.	1.4	17
21	Characterization of synovial fluid cytokine profiles in chronic meniscal tear of the knee. <i>Journal of Orthopaedic Research</i> , 2017, 35, 340-346.	1.2	40
22	JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia. <i>Endocrine</i> , 2017, 58, 106-114.	1.1	15
23	Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 386-404.	2.9	58
24	Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. <i>Scientific Reports</i> , 2017, 7, 13017.	1.6	37
25	Pharmacological and Biochemical Characterization of TLQP-21 Activation of a Binding Site on CHO Cells. <i>Frontiers in Pharmacology</i> , 2017, 8, 167.	1.6	19
26	Involvement of PPAR δ in the Anticonvulsant Activity of EP-80317, a Ghrelin Receptor Antagonist. <i>Frontiers in Pharmacology</i> , 2017, 8, 676.	1.6	33
27	JMV5656, A Novel Derivative of TLQP-21, Triggers the Activation of a Calcium-Dependent Potassium Outward Current in Microglial Cells. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 41.	1.8	14
28	Effects of ACL Reconstructive Surgery on Temporal Variations of Cytokine Levels in Synovial Fluid. <i>Mediators of Inflammation</i> , 2016, 2016, 1-7.	1.4	37
29	Progressive Seizure Aggravation in the Repeated 6-Hz Corneal Stimulation Model Is Accompanied by Marked Increase in Hippocampal p-ERK1/2 Immunoreactivity in Neurons. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 281.	1.8	26
30	Worth Remembering: Eugenio M \ddot{a} ller, MD, 1933-2015. <i>Pediatric Endocrinology Reviews</i> , 2016, 14, 4-8.	1.2	0
31	Pathophysiology of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?. <i>Current Medicinal Chemistry</i> , 2014, 21, 663-688.	1.2	171
32	Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3067-3075.	1.3	26
33	Growth Hormone Secretagogues Exert Differential Effects on Skeletal Muscle Calcium Homeostasis in Male Rats Depending on the Peptidyl/Nonpeptidyl Structure. <i>Endocrinology</i> , 2013, 154, 3764-3775.	1.4	10
34	Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury. <i>Journal of Orthopaedic Research</i> , 2013, 31, 315-321.	1.2	147
35	Protective but Not Anticonvulsant Effects of Ghrelin and JMV-1843 in the Pilocarpine Model of Status epilepticus. <i>PLoS ONE</i> , 2013, 8, e72716.	1.1	35
36	Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21. <i>Biochemical Journal</i> , 2012, 441, 511-522.	1.7	56

#	ARTICLE	IF	CITATIONS
37	Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues. <i>Pharmacological Research</i> , 2012, 66, 317-324.	3.1	11
38	Ghrelin anticonvulsive properties: Is it a matter of desacylation?. <i>Epilepsia</i> , 2012, 53, 1277-1278.	2.6	5
39	Beneficial effects of desacyl-ghrelin, hexarelin and EP-80317 in models of status epilepticus. <i>European Journal of Pharmacology</i> , 2011, 670, 130-136.	1.7	29
40	Central Nervous System-Acting Drugs Influencing Hypothalamic-Pituitary-Adrenal Axis Function. <i>Endocrine Development</i> , 2009, 17, 108-120.	1.3	39
41	Desacyl-ghrelin and synthetic GH secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by β -amyloid fibrils. <i>Journal of Neuroscience Research</i> , 2009, 87, 2718-2727.	1.3	73
42	Chronic intracerebroventricular injection of TLQP-21 prevents high fat diet induced weight gain in fast weight-gaining mice. <i>Genes and Nutrition</i> , 2009, 4, 49-57.	1.2	30
43	New Trisubstituted 1,2,4-Triazole Derivatives as Potent Ghrelin Receptor Antagonists. 3. Synthesis and Pharmacological in Vitro and in Vivo Evaluations. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 689-693.	2.9	70
44	Feeding behavior during long-term hexarelin administration in young and old rats. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 647-652.	1.8	9
45	Chronic intracerebroventricular TLQP-21 delivery does not modulate the GH/IGF-1-axis and muscle strength in mice. <i>Growth Hormone and IGF Research</i> , 2007, 17, 342-345.	0.5	13
46	Toward Potent Ghrelin Receptor Ligands Based on Trisubstituted 1,2,4-Triazole Structure. 2. Synthesis and Pharmacological in Vitro and in Vivo Evaluations. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5790-5806.	2.9	116
47	Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 962-976.	1.8	13
48	Synthesis and Pharmacological in Vitro and in Vivo Evaluations of Novel Triazole Derivatives as Ligands of the Ghrelin Receptor. 1. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1939-1957.	2.9	86
49	Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. <i>Journal of Endocrinological Investigation</i> , 2006, 29, RC16-RC18.	1.8	120
50	Intracerebroventricular acute and chronic administration of obestatin minimally affect food intake but not weight gain in the rat. <i>Journal of Endocrinological Investigation</i> , 2006, 29, RC31-RC34.	1.8	45
51	TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14584-14589.	3.3	150
52	Ghrelin regulates proliferation and differentiation of osteoblastic cells. <i>Journal of Endocrinology</i> , 2005, 184, 249-256.	1.2	173
53	Pyruvate and Satiety: Can We Fool the Brain?. <i>Endocrinology</i> , 2005, 146, 1-2.	1.4	8
54	Ghrelin in gastroenteric pathophysiology. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 843-848.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Hexarelin Modulates the Expression of Growth Hormone Secretagogue Receptor Type 1a mRNA at Hypothalamic and Pituitary Sites. <i>Neuroendocrinology</i> , 2004, 80, 52-59.	1.2	8
56	IGF-I stimulates proliferation of spontaneously immortalized human keratinocytes (HACAT) by autocrine/paracrine mechanisms. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 142-149.	1.8	16
57	Effects of hexarelin against acid-independent and acid-dependent ulcerogens in the rat. <i>Peptides</i> , 2004, 25, 2163-2170.	1.2	15
58	Ghrelin Expression and Actions: A Novel Peptide for an Old Cell Type of the Diffuse Endocrine System. <i>Experimental Biology and Medicine</i> , 2004, 229, 1007-1016.	1.1	48
59	Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: Evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 79-83.	1.8	5
60	Ontogeny and Tissue-Specific Regulation of Ghrelin mRNA Expression Suggest that Ghrelin Is Primarily Involved in the Control of Extraendocrine Functions in the Rat. <i>Neuroendocrinology</i> , 2003, 77, 91-99.	1.2	34
61	New Active Series of Growth Hormone Secretagogues. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1191-1203.	2.9	65
62	Ghrelin Plays a Minor Role in the Physiological Control of Cardiac Function in the Rat. <i>Endocrinology</i> , 2003, 144, 1787-1792.	1.4	58
63	Evidence for a Central Inhibitory Role of Growth Hormone Secretagogues and Ghrelin on Gastric Acid Secretion in Conscious Rats. <i>Neuroendocrinology</i> , 2002, 75, 92-97.	1.2	79
64	EP1572: A novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. <i>Journal of Endocrinological Investigation</i> , 2002, 25, RC26-RC28.	1.8	40
65	Short Ghrelin Peptides Neither Displace Ghrelin Binding In Vitro Nor Stimulate GH Release In Vivo. <i>Endocrinology</i> , 2002, 143, 1968-1971.	1.4	53
66	Ghrelin injected into the paraventricular nucleus of the hypothalamus of male rats induces feeding but not penile erection. <i>Neuroscience Letters</i> , 2002, 329, 339-343.	1.0	37
67	Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. <i>Histochemistry and Cell Biology</i> , 2002, 117, 511-519.	0.8	188
68	Ghrelin expression in gut endocrine growths. <i>Histochemistry and Cell Biology</i> , 2002, 117, 521-525.	0.8	57
69	Growth hormone-inhibiting activity of cortistatin in the rat. <i>Journal of Endocrinological Investigation</i> , 2001, 24, RC31-RC33.	1.8	26
70	Hexarelin, But Not Growth Hormone, Protects Heart from Damage Induced In Vitro by Calcium Deprivation Replenishment. <i>Endocrine</i> , 2001, 14, 109-112.	2.2	6
71	Penile erection induced by EP 80661 and other hexarelin peptide analogues: involvement of paraventricular nitric oxide. <i>European Journal of Pharmacology</i> , 2001, 411, 305-310.	1.7	16
72	Growth Hormone-Releasing Peptides And The Heart. <i>Growth Hormone</i> , 2001, , 195-206.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Differential Orexigenic Effects of Hexarelin and Its Analogs in the Rat Hypothalamus: Indication for Multiple Growth Hormone Secretagogue Receptor Subtypes. <i>Neuroendocrinology</i> , 2000, 72, 327-332.	1.2	51
74	EP 60761- and EP 50885-induced penile erection: structure-activity studies and comparison with apomorphine, oxytocin and N-methyl-D-aspartic acid. <i>International Journal of Impotence Research</i> , 2000, 12, 255-262.	1.0	28
75	EP 60761 and EP 50885, two hexarelin analogues, induce penile erection in rats. <i>European Journal of Pharmacology</i> , 2000, 404, 137-143.	1.7	21
76	Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Spontaneous and Growth Hormone (GH)-Releasing Hormone-Stimulated GH Secretion in Anorexia Nervosa ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2805-2809.	1.8	30
77	Growth Hormone-Independent Cardioprotective Effects of Hexarelin in the Rat ¹ . <i>Endocrinology</i> , 1999, 140, 4024-4031.	1.4	146
78	Glycosaminoglycans treatment increases IGF-I muscle levels and counteracts motor neuron death: A novel nonanticoagulant action. , 1999, 55, 496-505.		6
79	Glycosaminoglycans boost insulin-like growth factor-I-promoted neuroprotection: blockade of motor neuron death in the wobbler mouse. <i>Neuroscience</i> , 1999, 93, 565-572.	1.1	23
80	Growth Hormone and Hexarelin Prevent Endothelial Vasodilator Dysfunction in Aortic Rings of the Hypophysectomized Rat. <i>Journal of Cardiovascular Pharmacology</i> , 1999, 34, 454-460.	0.8	28
81	Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release. <i>European Journal of Pharmacology</i> , 1998, 360, 123-129.	1.7	86
82	Hexarelin Stimulation of Growth Hormone Release and mRNA Levels in an Infant and Adult Rat Model of Impaired GHRH Function. <i>Neuroendocrinology</i> , 1997, 65, 91-97.	1.2	15
83	Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: I a study on ad libitum fed and starved adult male rats. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 144-150.	1.8	29
84	Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: II. A study in the infant rat. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 151-154.	1.8	6
85	GROWTH HORMONE SECRETAGOGUES: FOCUS ON THE GROWTH HORMONE-RELEASING PEPTIDES. <i>Pharmacological Research</i> , 1997, 36, 415-423.	3.1	30
86	Regulation of Galanin by Dexamethasone in the Rat Anterior Pituitary and the Uterus. <i>Neuroendocrinology</i> , 1996, 64, 20-24.	1.2	7
87	Somatostatin Withdrawal as Generator of Pulsatile GH Release in the Dog: A Possible Tool to Evaluate the Endogenous GHRH Tone?. <i>Neuroendocrinology</i> , 1996, 63, 481-488.	1.2	27
88	Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat. <i>European Journal of Endocrinology</i> , 1996, 135, 481-488.	1.9	17
89	Role of the neuronal histaminergic system in the regulation of somatotrophic function: comparison between the neonatal and the adult rat. <i>Journal of Endocrinology</i> , 1996, 151, 195-201.	1.2	5
90	Involvement of Brain Catecholamines and Acetylcholine in Growth Hormone Hypersecretory States. <i>Drugs</i> , 1995, 50, 805-837.	4.9	32

#	ARTICLE	IF	CITATIONS
91	Long-term changes of somatotrophic function induced by deprivation of growth hormone-releasing hormone during the fetal life of the rat. <i>Journal of Endocrinology</i> , 1994, 140, 111-117.	1.2	32
92	Growth Hormone-Releasing Hexapeptide Is a Potent Stimulator of Growth Hormone Gene Expression and Release in the Growth Hormone-Releasing Hormone-Deprived Infant Rat. <i>Pediatric Research</i> , 1994, 36, 169-174.	1.1	35
93	Somatotropic Dysfunction in Growth Hormone-Releasing Hormone-Deprived Neonatal Rats: Effect of Growth Hormone Replacement Therapy. <i>Pediatric Research</i> , 1994, 36, 315-322.	1.1	13
94	GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. <i>Life Sciences</i> , 1994, 54, 1321-1328.	2.0	132
95	Calcium signaling and secretory responses in agonist-stimulated pituitary gonadotrophs. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 41, 453-467.	1.2	29
96	Age-dependent modulation by galanin of growth hormone release from rat pituitary cells in culture. <i>Life Sciences</i> , 1990, 47, 1861-1866.	2.0	19
97	Involvement of the somatostatin and cholinergic systems in the mechanism of growth hormone autofeedback regulation in the rat. <i>Journal of Endocrinology</i> , 1988, 117, 273-281.	1.2	66
98	Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin. <i>Journal of Endocrinology</i> , 1986, 111, 271-278.	1.2	185